OncoSil Medical Doubles Dose Sales Amid Promising Pancreatic Cancer Trial Data

Record Sales and Growing Market Footprint

OncoSil Medical Ltd (ASX: OSL) has delivered a standout first half for FY26, reporting a doubling in dose sales compared to the same period last year. This surge in demand for its OncoSil™ device, used in the treatment of locally advanced pancreatic cancer, has translated into a 184% increase in cash receipts, reaching $1.2 million. The company’s expanding footprint across Europe, including inaugural treatments in Germany, the UK, Portugal, and Türkiye, underscores growing clinical adoption and confidence in the technology.

Encouraging Clinical Evidence Bolsters Confidence

Supporting this commercial momentum are promising clinical developments. Preliminary data from the investigator-initiated PANCOSIL Phase 1-2 study, presented at the CIRSE 2025 Congress, demonstrated the safety and feasibility of CT-guided percutaneous administration of OncoSil™, with a 90% technical success rate and no procedure-related deaths among 20 patients. Notably, patients receiving OncoSil™ alongside FOLFIRINOX chemotherapy showed a median overall survival of 20.6 months, significantly exceeding historical benchmarks.

Complementing these findings, interim analysis from the OSPREY post-marketing registry revealed median overall survival of up to 22 months in first-line patients treated with OncoSil™ and gemcitabine-based chemotherapy, with a favourable safety profile and minimal serious adverse events. These real-world outcomes reinforce the device’s potential to improve survival in a cancer type traditionally associated with poor prognosis.

Advancing Clinical Trials and Manufacturing Capabilities

OncoSil has also marked the completion of the last patient last visit milestone in its TRIPP-FFX clinical trial, which evaluates the device in combination with FOLFIRINOX chemotherapy. Final data analysis is underway, with results anticipated in the first half of calendar 2026. Regulatory submissions to expand the CE Mark label to include this chemotherapy regimen are planned for the second half of 2026.

Operationally, the company achieved a successful radioactive production run at its new Sydney manufacturing facility, a critical step towards in-house device production. This move is expected to enhance supply chain resilience and reduce unit costs, supporting improved gross margins once regulatory approvals are secured.

Leadership Transition and Capital Strengthening

Corporate governance saw a significant shift with Dr Thomas Duthy appointed Non-Executive Chairman in October 2025, bringing extensive healthcare and corporate development experience. Meanwhile, former Chairman Douglas Cubbin retired in November 2025 after contributing to the company’s strategic direction during a pivotal growth phase.

Financially, OncoSil strengthened its balance sheet through an $8 million capital raise in early 2026, comprising a placement and entitlement offer to sophisticated and professional investors. This capital injection, alongside a $1.84 million R&D tax incentive refund, provides the company with the resources to accelerate commercial expansion and regulatory efforts.

Looking Ahead

Despite reporting a net loss of $4.53 million for the half-year, OncoSil’s operational and clinical progress positions it well for growth. The company remains focused on broadening patient access, advancing regulatory approvals, and delivering meaningful outcomes for those affected by pancreatic cancer; a disease with limited treatment options and historically poor survival rates.